Illumina

August 10, 2018
Democratising DNA: 23andMe & GSK Collaboration Raises Privacy & Data Quality Concerns - Can Blockchain Offer a Disruptive Solution?

Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

March 27, 2018

All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation

January 11, 2017
Illumina’s NovaSeq Platform Aims for the $100 Human Genome, but is it Good Business?

Illumina’s NovaSeq Platform Targets the $100 Human Genome, but do they Risk Self-Cannibalisation?

Illumina utilised their showcase at the JP Morgan Conference to announce its new DNA sequencers, the NovaSeq 5000 and NovaSeq 6000, promising that by the end of the […]
March 17, 2016
Evolution M&A Analysis: Evaluating Potential Acquisition Targets for Thermo Fisher Scientific

Evolution M&A Analysis: Evaluating Potential Acquisition Targets for Thermo Fisher Scientific

A recent mixed securities shelf registration filing by Thermo Fisher Scientific has prompted speculation from industry insiders and investors, with prominent advisors predicting further acquisitions for […]
September 17, 2015
Thermo Fisher and Illumina Prepare for Round Two of the Next-Gen Sequencing Battle

Thermo Fisher and Illumina Prepare for Round Two of the Next-Gen Sequencing Battle

Earlier this month Thermo Fisher Scientific announced the launch of two novel next-generation sequencing (NGS) instruments, the Ion S5 and the Ion S5 XL benchtop systems, […]
November 4, 2014

Illumina Report Record Financial Result for Q3 2014

Illumina Reports Record Financial Results for Third Quarter of Fiscal Year 2014 Illumina, Inc. announced its financial results for the third quarter of 2014. Third quarter […]
Contact Us